Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?

[1]  Jordi Giralt,et al.  Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Corvò,et al.  Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Decker,et al.  Cisplatin Versus Cetuximab With Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Garden,et al.  Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus–associated oropharyngeal cancer , 2016, Head & neck.

[5]  W. Shi,et al.  Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck , 2016, American journal of clinical oncology.

[6]  A. Levy,et al.  Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. , 2015, Cancer treatment reviews.

[7]  Johannes A Langendijk,et al.  Advances in Radiotherapy for Head and Neck Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[9]  T. Strom,et al.  Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. , 2015, Oral oncology.

[10]  A. Dueñas-González,et al.  Emerging drugs for the treatment of cervical cancer , 2015, Expert opinion on emerging drugs.

[11]  J. Pignon,et al.  Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  A. Cmelak,et al.  Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. , 2015, The Lancet. Oncology.

[13]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[14]  Ming-Huang Chen,et al.  Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment , 2014, BioMed research international.

[15]  S. Strome,et al.  The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. , 2014, Oral oncology.

[16]  D. Hartl,et al.  Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status. , 2014, European journal of cancer.

[17]  J. Bourhis,et al.  Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas , 2014, Strahlentherapie und Onkologie.

[18]  G. Calais,et al.  Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Cyrus Chargari,et al.  Radiation therapy and immunotherapy: implications for a combined cancer treatment. , 2013, Critical reviews in oncology/hematology.

[20]  M. Brandwein-Gensler,et al.  Human Papillomavirus in Non-Oropharyngeal Head and Neck Cancers: A Systematic Literature Review , 2012, Head and Neck Pathology.

[21]  J. Pignon,et al.  Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. , 2011, Journal of clinical epidemiology.

[22]  P. Lassen.  The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[24]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  A. Garden,et al.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Weber,et al.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. , 2003, The New England journal of medicine.

[27]  J. Ensley,et al.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.